biotech · Pulmonary Disease, Chronic Obstructive · Symptomatic Neurogenic Orthostatic Hypertension · TBPH
Theravance Biopharma Ireland
Theravance Biopharma Ireland Umited
Theravance Biopharma Ireland is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TBPH. Primary therapeutic focus areas include Pulmonary Disease, Chronic Obstructive, Sympt
Company details
- Status
- Public
- HQ
- 901 Gateway Blvd., South San Francisco, CA 94080, US
- Founded
- 2014
- Employees
- 177
- Programs
- 57
- Drugs
- 18
- Patents
- 635
TD-3504
Phase 1 · small molecule · Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
TD-3504 for Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects is a Phase 1 program (small_molecule) at Theravance Biopharma Ireland Umited with 1 ClinicalTrials.gov record(s).
Internal code 0146
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Theravance Biopharma Ireland Umited
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
- Status
- completed
- Trials
- 1